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The phytochemical curcumin may improve translocation of the cystic ﬁbrosis transmembrane regulatory
(CFTR) protein in lung epithelium and therefore be helpful in the treatment of cystic ﬁbrosis (CF)
symptoms. However, previous studies often use commercial curcumin that is a combination of curcumin,
demethoxycurcumin and bisdemethoxycurcumin which could affect the investigated cells differently. In
the present study, we investigated the potential difference between curcumin, bisdemethoxycurcumin
and dimethoxycurcumin on the epithelial tight junction complex, in the bronchial epithelial cell line
VA10, by measuring transepithelial electrical resistance (TER), immunoﬂuorescence and western blotting
of tight junction proteins. The curcuminoids were complexed with hydroxypropyl-γ–cyclodextrin for
increased solubility and stability. Curcumin (10 mg/ml) increased the TER signiﬁcantly after 24 h of
treatment while four times higher concentration of bisdemethoxycurcumin was required to obtain si-
milar increase in TER as curcumin. Interestingly, dimethoxycurcumin did not increase TER. Curcumin
clearly affected the F-actin structures both apically and basolaterally. These results begin to deﬁne
possible effects of curcuminoids on healthy bronchial epithelia and shows that difference in the phenyl
moiety structure of the curcuminoids inﬂuences the paracellular epithelial integrity.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Curcumin is a phytochemical, found in the dried rhizome of the
plant Curcuma longa L. The dried rhizome, called turmeric, is often
used as spice and is a common ingredient in curry powder.
Amount of curcumin in turmeric is commonly around 2–8% [1]. In
Southeast Asia, turmeric is not only used as a spice or a coloring
agent but is also used to externally treat wounds, inﬂammation
and tumors, liver-and gall diseases among other illnesses. Curcu-
min has been studied from a pharmaceutical perspective regard-
ing its antioxidant, anti-inﬂammatory and anti-cancer properties
[2]. It is currently one of nearly twenty possible therapies against
cystic ﬁbrosis (CF) in development according to Cystic Fibrosis
Foundation. A phase I clinical trial, to assess safety and dosage
parameters when given to CF patients, has been initiated. CF is ar B.V. This is an open access article
s; CFTR, cystic ﬁbrosis trans-
sistance; TJs, tight junctionslethal, hereditary disease caused by a mutation in the gene that
codes for the cystic ﬁbrosis transmembrane regulator (CFTR)
chloride channel protein [3–5] causing the misfolded CFTR protein
to be degraded [6]. This disease is characterized by chronic re-
spiratory infections and inﬂammation and irrespective of in-
creased knowledge of the CF pathology, the mean predicted sur-
vival of CF patients is around 40 years [7]. Studies have shown that
if the mutant CFTR protein could relocate from the endoplasmic
reticulum to the plasma membrane, it could restore the chloride
pump activity [8].
Curcumin may improve the translocation of the CFTR chloride
channel protein in lung epithelium [9] although recent studies
have not been able to conﬁrm those results [10–12]. Berger and
colleagues discovered that curcumin stimulated the activity of the
CFTR channels by elongating the channel opening time and these
effects were dose dependent, reversible and ATP dependent [13].
Curcumin also increased the chloride transport of CFTR channels
in normal lung epithelia but was unsuccessful in the defected CFTR
channels [13]. Similarly, it has been reported that curcumin opens
CFTR channels but unlike the study by Berger, the CFTR openingunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Tight junctions (TJs) control paracellular ion- and water
transport and are necessary for the tightness of the epithelium and
are a key part in lung defenses [15]. CF patients often acquire
chronic pulmonary infections by the bacteria Pseudomonas aeru-
ginosa that disrupts the epithelial barrier integrity [16,17]. The
macrolide antibiotic azithromycin has proven beneﬁcial with CF
patients in concentrations not affecting the bacterial count [18,19].
Interestingly, this macrolide also increased the paracellular in-
tegrity in normal bronchial epithelial cells [20] and protected the
epithelium during P. aeruginosa infection at concentrations not
affecting the bacterial count [21]. When considering the potential
role of curcumin in CF pathogenesis, it is important not only to
consider the CFTR translocation but also the effect on paracellular
integrity of normal epithelium.
Most studies use commercial grade curcumin [14,22,23] which
is composed of curcumin (75–85%), demethoxycurcumin (10–20%)
and bisdemethoxycurcumin (5%) [24]. As a result, valid concerns
arise regarding the use of this curcumin combination since the
effects of one curcuminoid could be masked by other curcumin
components. Additionally, previous limitations with the use of
curcumin is its poor solubility at acid and physiological pH and
rapid hydrolysis at basic pH [25]. This results in the use of DMSO
and/or ethanol as a solvents [22,23,26], which can have adverse
effects on the investigated cells [27,28]. By complexing curcumins
with cyclodextrins (CDs) in aqueous solutions [29,30], the solubi-
lity and stability can be increased [30,31]. Here, we investigate
whether curcumin and the curcuminoids dimethoxycurcumin and
bisdemethoxycurcumin (Fig. 1), complexed with CDs, increase the
paracellular epithelial integrity and if those effects are different
between derivatives.2. Materials and methods
2.1. Curcuminoid solutions
Curcumin (diferuloylmethane) and curcuminoids (bisde-
methoxycurcumin and dimethoxycurcumin) were synthesized and
characterized as previously described [31,32]. The hydroxypropyl-
γ–CD (HPγCD) improves the solubility of curcumin and theFig. 1. The curcuminoids curcumin, bisdemethoxycurcumin and dimethox-
ycurcumin have different substitutions on the phenyl ring.curcuminoids dimethoxycurcumin and bisdemethoxycurcumin
[31] and was therefore chosen as a complexing agent. The stock
solutions of the curcumin and the curcuminoids contained 200 mg/
ml curcumin compound, 5% v/v dimethylsulfoxide (DMSO) and
15% w/v hydroxypropyl-γ-cyclodextrin (HP-γ–CD, Cavasols WB
HP Pharma, Wacker- Fine Chemicals, Germany) in phosphate
buffer saline (PBS) and were all stored away from light in at 5–8 °C.
Test solutions were prepared by dissolving appropriate amounts of
stock solutions into the DMEM-F12þUltroser-G cell culture med-
ium. Amount of CD/DMSO solution that curcumin and curcumi-
noids were dissolved in was also tested for possible effects on TER
and TJs.
2.2. Cell culture
The newly established and validated bronchial epithelial cell
line, VA10 [33,34] was used between passages 13–20. The cells
were maintained in 75 cm2 ﬂasks in a humidiﬁed incubator at
37 °C (5% CO2) containing bronchial epithelial growth medium
(BEGM, Cambrex, East Rutherford, NJ, USA). Mediumwas aspirated
and changed every other day with a fresh, prewarmed medium.
The cells were seeded at the density of 1105 cells/cm2 on the
upper chamber of Transwell ﬁlters (pore size 0.4 mm, 12 mm dia-
meter, polyester membrane, Corning Costar Corporation) and
cultured in BEGM medium for 5-6 days, with 0.5 ml medium ad-
ded to the apical side and 1.5 ml medium to the basolateral side.
Subsequently, the cells were cultured in Dulbecco’s minimum es-
sential medium Ham’s F12 1:1 (DMEM/F-12) medium (Gibco,
Burlington, Canada) supplemented with 2% Ultroser G serum
substitute (Pall Life Sciences, Cergy-Saint-Christophe, France) and
penicillin/streptomycin. Medium was changed every other day. For
morphological analysis and western blot proteins analysis, the
cells were seeded on a 6 well plates (Falcon Multiwell 6 Well,
Becton Dickinson, NJ, USA) at 2105 cells/well and cultured in
BEGM.
2.3. Transepithelial Electrical Resistance (TER) Measurement
TER of VA10 cell layers was measured with Millicell-ERS
volthometer (Millipore, MA, USA). The corrected TER value was
obtained after subtraction of the background from the cell-free
culture insert.
2.4. Immunocytochemistry
VA10 cells were ﬁxed for 10 min with 3.7% formaldehyde,
permeabilized with 0.1% Triton X-100 for 5 min and then blocked
with 10% fetal bovine serum for 5 min. The following primary
antibodies were used (diluted in PBS): Mouse anti-human claudin-
1 (IgG1, 1:125), mouse anti-human ZO-1 (IgG1,1:50) and rabbit
anti-human occludin (1:20) and were all purchased from Zymed
(CA, USA). Cells were incubated with primary antibodies for
30 min followed by incubation with isotype speciﬁc Alexa Fluor
secondary antibodies (Invitrogen, Oregon, USA,1:1000) and To-
Pro-3 (Invitrogen) for nuclear staining (1:500) for 30 min. Alexa
Fluor 488 phallotoxin (Invitrogen) was used for F-actin staining
(1:40), incubated for 30 min.
2.5. Confocal microscope
Immunoﬂuorescence images were obtained using Zeiss LSM
5 Pa confocal laser scanning microscope (CLSM, Carl Zeiss AG,
Munich, Germany) with Plan-Neoﬂuar 20 , 40 and Plan-
Apochromat 63 oil immersion lenses. VA10 cell layers were
mounted with Fluoromount-G (SouthernBiotech, Birmingham,
USA) and coverslips before visualization.
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For quantiﬁcation of F-actin ﬂuorescence, images were cap-
tured with confocal microscopy at the focal plane where F-actin
apical staining was most prominent. All images used for quanti-
ﬁcation were acquired using the same confocal settings. Quanti-
ﬁcation using immunoﬂuorescence images was performed using
Fiji (ImageJ) software.
2.7. Western blotting
After the cells grown in 6 well culture plates were treated with
PBS, curcumin or curcuminoids, they were lysed in RIPA buffer
containing a protease inhibitor cocktail (Aprotinin, PMSF and
Na3VO4). The cells were then scraped from the ﬁlters and soni-
cated for 2 min followed by centrifugation at 12,000 g for 20 min
at 4 °C. The supernatant was collected and the protein con-
centration determined with the Bradford assay. Equal amounts of
proteins, as determined by the Bradford method [35], were loaded
and run on a NuPAGE 10% Bis-Tris gel (Invitrogen, Carlsbad, USA)
and transferred to a polyvinylidine diﬂuoride membrane (In-
vitrogen). The membranes were blocked for 1 h with 5% skimmed
milk in 0.25% Tween/PBS and incubated with the primary anti-
bodies mouse anti-E-cadherin (BD Bioscience, IgG2a 1:330),
mouse anti-claudin-1 (IgG1,1:500) or rabbit anti-occludin (1:1000)
overnight, followed by incubation with secondary antibodies
(1:2000) for 1 h. Protein bands were visualized using enhanced
chemiluminescence system and Hyperﬁlm (Amersham Bioscience,
England).
2.8. Morphological analysis
After reaching conﬂuency the cells were incubated with cur-
cumin or curcuminoids. Images were captured on day 1, 4 and
6 after beginning of treatment using Leica DFC320 digital imaging
system.Fig. 2. Different effects of curcumin and curcuminoids on TER in human airway epith
support ﬁlters. After reaching conﬂuency, curcumin (A, B), bisdemethoxycurcumin (C) or
measured using a Millicell-ERS electrical resistance system. Data are given as mean7S2.9. Calculations and data analysis
All data were reported as mean7standard deviation with n
representing number of experiments. Unpaired, two tailed Stu-
dent's t-test was done in GraphPad to compare two means with
the difference considered to be statistically signiﬁcant when
po0.05.3. Results and discussion
3.1. Curcumin and bisdemethoxycurcumin increase transepithelial
electrical resistance (TER) signiﬁcantly in human airway epithelia in
vitro
To determine if the curcuminoids increase the paracellular in-
tegrity of epithelia and consequently be beneﬁcial for haltering the
CF progression, TER was measured. Indeed, addition of 10 mg/mL
curcumin to the basolateral side of the epithelium every other day
resulted in signiﬁcant increase in TER after 24 h treatment
(Fig. 2A), 3-fold increase compared to initial value. The increase in
TER was not observed in the initial period of the measurements of
60 min (data not shown). After 6 days of treatment, the TER in-
crease had leveled off at around 10-fold increase from initial value.
Curcumin at 1 mg/mL did not increase TER as can be seen in Fig. 2A.
The increase in TER was not as apparent with 40 mg/mL curcumin,
reaching signiﬁcant higher TER levels compared to control after
5 days of treatment (Fig. 2B). The CD/DMSO control solution did
not affect the TER values compared to normal control epithelium
(Fig. 2A).
To explore whether the effects of curcumin on TER were spe-
ciﬁc to the curcumin structure, two other curcuminoids, bisde-
methoxycurcumin and dimethoxycurcumin, were investigated
(Fig. 2C and D). Interestingly, these curcuminoids had markedly
different effects on the bronchial epithelia. Two days of treatment
with 40 mg/mL bisdemethoxycurcumin resulted in signiﬁcantelia in vitro. Human airway epithelial cells were cultured on Transwell permeable
dimethoxycurcumin (D) were added to the basolateral side of the epithelia. TER was
D (n¼3).
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Conversely, dimethoxycurcumin did not affect the TER values in
any of the concentrations investigated (Fig. 2D). After 6 days of
treatment with this curcuminoid, the epithelial lining appeared to
be less continuous than the control epithelium (Fig. A1), sug-
gesting possible adverse effects on the epithelium. The dose de-
pendent effect of curcumin and the different effects of curcumin
and the other curcuminoids on TER measurements indicate a
possible agonistic/antagonistic activity that warrants further
exploration.
3.2. Curcumin affects F-actin localization but not expression of the TJ
proteins claudin-1 and occludin and the adherens protein E-cadherin
The TJs are membrane bound proteins that produce apical to
basolateral polarity [36] and form a paracellular permeability
barrier that limits the permeation to small, uncharged solutes [37].
The TJ complex is dynamic in nature, with its junctional proteins
affected by various internal and external stimuli [38]. TER is con-
sidered a good indicator of the functional activity of the tight
junctions [39]. Since curcumin increased TER, it could possibly
affect the expression or localization of TJ proteins or related
components. Intracellularly, there are TJ associated proteins such
as the members of the ZO family that connect to the actin cytos-
keleton which is often affected when the TJ complex is altered
(reviewed in [40]). In particular, the actin cytoskeleton is involved
in modiﬁcations of the tight junction barrier [38] with redis-
tribution of actin ﬁlaments been observed to be crucial to the in-
duced barrier formation of endothelial cells by sphingosine
1-phosphate [41]. As can be seen in Fig. 3A and B, altered staining
patterns of both apical and basolateral F-actin was observed after
treatment with curcumin. The total amount of apical F-actin ﬁbers,
as determined by quantiﬁcation of ﬂuorescence, was signiﬁcantly
reduced after treatment with 1 μg/ml curcumin and this reduction
was highly signiﬁcant after treatment with 10 μg/ml curcumin as
Fig. 3C shows. Additionally, basolateral actin was not as ﬁla-
mentous compared to the control epithelium (Fig. 3B). Curcumin is
a known upstream inhibitor of NF-κ B [42], a transcription factor
that has been shown to interact with the actin cytoskeletonFig. 3. The effects of curcumin on adh[43,44]. A possible relationship between the actin rearrangement
and increased TER observed in the current study with the known
inhibition of the NF-κ B pathway could therefore be possible.
Curcumin affects the localization of F-actin ﬁlaments. Bronchial
epithelial cells were treated with control, CD/DMSO vehicle or
curcumin (1 and 10 mg/mL) for 14 days on Transwell ﬁlters. Cur-
cumin at 10 mg/mL clearly affects both apical (A) and basolateral
(B) actin ﬁlaments. C) Quantiﬁcation of the F-actin ﬂuorescent
intensity at the apical sites shows signiﬁcant decrease in apical
F-actin staining after treatment of 1 μg/ml and 10 μg/ml curcumin.
Values represent relative ﬂuorescent intensity in arbitrary units
(AU), n¼5–6 and are expressed as mean7SD. * po0.05 compared
to control, ** po0.005. D) Expression of occludin, claudin-1 and
E-cadherin after curcumin treatment. Bronchial epithelial cells
were treated with control, CD/DMSO vehicle or curcumin
(10 mg/mL), for 4, 10 and 14 days and the expression determined by
western blotting. Claudin-1 expression appears to be gradually
changed for both the CD/DMSO control and curcumin treatment.
To further explore these possible effects on the TJ complex, the
expression of occludin, claudin-1 and E-cadherin was investigated
after treatment with 10 mg/ml curcumin (Fig. 3B). Western blotting
of occludin revealed a double band at 60 kDa but no alterations
in the expression at the different time points investigated.
E-cadherin is a membrane spanning adhesion protein, essential for
formation and maintenance of normal epithelium [45]. Although
investigations have indicated that curcumin may down-regulate
its expression [46] this was not observed in the current study.
Claudins are one of the main components of the tight junction
complex that decide both TER and charge speciﬁcity [47,48]. Over
twenty claudins have been identiﬁed and their expression pattern
is speciﬁc for each epithelial type [49,50]. Thus it is indicated that
different composition of claudins attribute to different properties
of epithelial tissues [47]. Watari and colleagues reported that
curcumin (3.7 mg/ml) was a claudin-4 inducer, with concomitant
increase in TER of 170% of initial value after 48 h of treatment
[51]. In the current study, both the CD/DMSO vehicle and curcumin
(10 mg/ml) appeared to reduce the expression of claudin-1, there-
fore the direct effects of curcumin on the claudin-1 expression
remain inconclusive.erens and tight junction proteins.
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chial epithelia. Curcumin was more efﬁcient in increasing TER
compared to bisdemethoxycurcumin, while dimethoxycurcumin
did not affect TER. Rearrangement of the basolateral F-actin stress
ﬁbers and its decreased staining at the apical surface was observed
after curcumin treatment. These results show that different cur-
cuminoids can have different effects on the epithelia, indicating
that future studies would beneﬁt from using pure curcuminoids.
The effects of curcumin towards the increased bronchial para-
cellular integrity could be a part of its beneﬁcial effects in treat-
ment of CF.Acknowledgment
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